内容教案讲稿2015个体化alan rena act.pptxVIP

Alan Lau, Pharm.D. Professor and Director, Clinical Pharmacy Education University of Illinois at Chicago College of Pharmacy;June, 2013;November, 2015;July, 2014;October, 2015;Today’s Pharmacist; Why Chronic Kidney Disease ? ;Data Source: Reference table D.1. Abbreviation: ESRD, end-stage renal disease.;Etiology of Chronic kidney disease;CKD population;Source: Chen, 2015 Blood Purification Forum, Chinese Society of Nephrology. (陈香美，中华医学会肾脏病学分会2015年血液净化论坛);20;Overweight and obese adults in China: 38.5% (2010);Therapeutic issues of Chronic Kidney Disease ;Normal functions of kidney;Complications of chronic kidney disease (CKD); ;12 medications: 10 at home, 2 at dialysis unit N=10,474 patients;IWD: Indication without drug, DWI: Drug without indication, IDS: Improper drug selection LAB: Lab monitoring, ADR: Adverse drug reaction, FRD: Failure to receive drug, OD: Overdose, UD: Subtherapeutic dose, DI: Drug interaction [Manley HJ, AJKD, 2005];Major CKD complications : Anemia Mineral and bone disorder (MBD) ;;Anemia: Etiology;Anemia: Significance;Erythropoietin;Erythropoiesis stimulating agents (ESA);FDA: Target Hgb level for ESA therapy;KDIGO anemia treatment guidelines 2012;ESA use and consequences;National Kidney Foundation. Am J Kidney Dis. 2006;47(suppl 3):S1-S146. ;Adapted from Macdougall IC, et al. Kidney Int. 1996;50:1694-1699.;Assessment of iron stores;Assessment of iron stores;Assessment ofiron stores;Assessment of body iron;KDIGO anemia treatment guidelines 2012 ;Iron therapy for CKD patientsKDIGO guidelines 2012;Major CKD complications : Anemia Mineral and bone disorder (MBD) ;Feedback Loops inSECONDARY HYPERPARATHYROIDISM;Progression of Parathyroid Hyperplasia;Clinical presentations;Pharmacotherapy;Goals of Treatment;Outpatient Dialysis Unit;Patient care Rounds;Pharmacotherapy;Maintenance of Medication Lists;Pharmacotherapy compliance and dispensing;Participation in Lab Review m